Saturday 17 October 2026
Export MREO’s income statement to Excel — free account
Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.
0.30
0.01
−3.23%
Follow MREO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 1.08 | 0.69 | 1.45 | 0.30 | 0.61 | 2.23 | 0.20 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 8.48 | 4.25 | 4.71 | 1.85 | 2.45 | 5.02 | 3.84 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 37 | 50 | 38 | 49 | 36 | 33 | 36 | 39 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 1.02 | 0.00 | 0.30 | 0.00 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 50 | — | 10 | — | 1 | ||||
| Gross margin, % | — | — | — | — | — | 50.89 | 0.00 | 74.26 | — | 73.40 | |||||
| EBT | — | — | (50) | (53) | (214) | 20 | (43) | (30) | (43) | (42) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 39.05 | 0.00 | (299.98) | 0.00 | (8,375.60) | |||||
| Net income | — | — | (50) | (53) | (214) | 20 | (42) | (29) | (43) | (42) | |||||
| Depreciation | — | — | 0 | 2 | 2 | 1 | 0 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.48 | 0.00 | 0.08 | 0.00 | 0.00 | ||||
| Earnings | — | — | (3.00) | (2.49) | (3.08) | 0.14 | (0.37) | (0.20) | (0.29) | (0.26) | |||||
| Cash flow | — | — | (2.17) | (3.28) | (0.54) | (0.07) | (0.40) | (0.16) | (0.22) | (0.19) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.03 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (2.17) | (3.28) | (0.50) | (0.07) | (0.40) | (0.16) | (0.23) | (0.20) | |||||
| Book value | — | — | 3.07 | 2.87 | (0.28) | 1.15 | 0.43 | 0.38 | 0.41 | 0.26 | |||||
| Shares, m | — | — | 14 | 18 | 68 | 106 | 121 | 132 | 148 | 159 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | ||||
| P/S | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | |||||
| P/B | — | — | — | — | — | 0.00 | — | 6.00 | — | 1.64 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | 2.11 | — | (11.45) | — | (0.98) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (31) | (59) | (36) | (7) | (49) | (21) | (33) | (31) | ||||
| Capex | — | — | 0 | 0 | 2 | (1) | 0 | 0 | (1) | 0 | |||||
| Free cash flow | — | — | (31) | (59) | (34) | (8) | (49) | (22) | (34) | (31) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 24 | 1 | 27 | 119 | 51 | 54 | 61 | 41 | ||||
| Total debt | — | — | 29 | 26 | 21 | 20 | — | 4 | — | — | |||||
| Net debt | — | — | (8) | 5 | (9) | (110) | (68) | (53) | (70) | (41) | |||||
| Shareholders’ equity | — | — | 44 | 51 | (19) | 121 | 51 | 51 | 61 | 41 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (44.45) | (219.76) | 13.74 | (33.61) | (40.95) | (60.54) | (68.48) | ||||
| ROIC | — | — | (82.38) | (55.60) | 0.00 | (161.74) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 0.00 | (93.52) | (1,305.77) | 34.38 | (48.98) | (57.81) | (77.58) | (82.21) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2025
Charts ten years each
Mereo BioPharma Group plc - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INKT MiNK Therapeutics, Inc. | $50.7M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LONA LeonaBio, Inc. | $49.8M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $49.8M | — (loss-making) | — (loss-making) | −43.79% (below 0%: shrinking) | n/m | −33.16% (below 0%: shrinking) | 100.00% | (1,690.39%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $49.3M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | |
| HYPD Hyperion DeFi, Inc. | $49.0M | — (loss-making) | 3.6× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $48.5M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| ELTX Elicio Therapeutics, Inc. | $48.2M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ACET Adicet Bio, Inc. | $48.1M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $47.8M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $48.7M | — | — | +256.11% | — | +10.34% | 0.00% | 0.00% |
Mereo BioPharma Group plc - Sponsored ADR (MREO) key facts
- Concern: Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023.
- Mereo BioPharma Group plc - Sponsored ADR (MREO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MREO traded at $0.30, a market capitalization of $49.3 million.
- Return on equity was −82.2% and debt-to-equity 0.00.
- Its Altman Z-score is −9.11 (distress zone) for fiscal 2025.